Undesirable distant effects following botulinum toxin type a injection

Clinical Neuropharmacology

Volumn 31, Issue 5, 2008, Pages 272-280

  Roche, Nicolas ^a,b   Schnitzler, Alexis ^a   Genêt F, François ^a   Durand, Marie Christine ^a   Bensmail, Djamel ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Adverse effects; Botulinum toxin type A (BoNTA); Diffusion; Electromyography

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BLURRED VISION; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DENERVATION; DIPLOPIA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ELECTROMYOGRAPHY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUSCLE BIOPSY; MUSCLE WEAKNESS; NERVOUSNESS; PRIORITY JOURNAL; PTOSIS; REINNERVATION; RETROSPECTIVE STUDY; SPASTICITY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FOLLOW UP; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; BOTULINUM TOXIN TYPE A; COHORT STUDIES; ELECTROMYOGRAPHY; FATIGUE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE SPASTICITY; MUSCLE WEAKNESS; RETROSPECTIVE STUDIES;

EID: 65849406333     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815cba8a     Document Type: Article

References (32)

1. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989; 65(762):208-210.
2. Schantz EJ. Historical perspective. In: Jankovic J Hallet M. Therapy With Botulinum Toxin. New York: Marcel Dekker; 1994:XXIII-XXVI.
3. Aoki KR. Pharmacology and immunology of botulinum toxin type A. Clin Dermatol 2003;21: 476-480.
4. Guérit J-M, Maugière F, Plouin P, et al. Guide pratique de neurophysiologie clinique. Recommandations de la fédération internationale de neurophysiologie clinique. Edition scientifique et médicale. Elsevier; 2002.
5. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006;13:10-19.
6. Ranoux D, Gury C, Fondari J, Mas JL, Zuber M. Respective potencies Botox and Dysport: a double blind randomised crossover study in cervical dystonia. J Neurol Neurosurg and Psychiatry 2002; 72:459-462.
7. Odergren T, Hjaltason H, Kaakkola S. A double blind randomised parallel study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
8. Borodic GE, Ferrante R, Pearce LB, et al. Histologic assessment of dose related diffusion and muscle fibre response after therapeutic botulinum A toxin injections. Mov Disord 1994;9:31-39.
9. Dutton JJ. Botulinum A toxin in the treatment of craniocervical muscle spasms: short and long term, local and systemic effects. Surv Ophthalmol 1996;41:51-65.
10. Kessler KR, Skutta M, Benecke R. Long term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 1999;246:265-274.
11. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
12. Bhatia KP. Generalised muscular weakness after botulinum toxin injection for dystonia: a report of two cases. J Neurol Neurosurg Psychiatry 1999;67: 90-93.
13. Eleopra R, Tugnoli V, Quatrale R. Distant and focal botulism-like syndrome after botulinum toxin serotype A and F injections. Neurology 2000; 54(A):199.
14. Del Popolo G. Botulinum A toxin in the treatment of detrusor hyperreflexia. Neurol Urodyn 2001;20: 522-524.
15. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum toxin A: a double blind study. Arch Phys Med Rehabil 1990;71:24-26.
16. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002; 40:599-600.
17. Tugnoli V, Eleopra R, Quatrale R, et al. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol 2002;147: 808-809.
18. Le Witt PA, Trosh RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997;12:1064-1067.
19. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993;81:33-37.
20. Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-555.
21. Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991;14:672-675.
22. Olney RK, Aminoff MJ, Gelb DJ, et al. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988; 38:1780-1783.
23. Habermann E. 125I labeled neurotoxin from clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol 1976;281:47-56.
24. Wiegand H, Wellhoner HH. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 1977;298: 235-238.
25. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002;81: 355-363.
26. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004;140: 1351-1354.
27. Kim HS, Hwang JH, Jeong ST. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003;45: 200-206.
28. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006;13(suppl 4):10-19.
29. Bihari K. Safety, effectiveness and duration of effect of Botox after switching from Dysport for blepharospasm, cervical dystonia and hemifacial spasm. Curr Med Res Opin 2005;21:433-438.
30. Ranoux D, Gury C, Fondarai J et al. Respective potencies of Botox and Dysport: a double blind randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72: 459-462.
31. Dewland P, Sandeep HC, Ward AB. Migration properties of two different botulinum toxin type A formulations in the forehead. Joint Meeting of the American Society of Neurorehabilitation and American Congress of Rehabilitation Medicine, Boston, September 2006.
32. Trontelj JV, Stalberg E, Mihelin M. Jitter in the muscle fibre. J Neuro Neurosurg Psychiatry 1990; 53:49-54.